Search Bar & Filters
Found 31 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating whether calderasib combined with subcutaneous pembrolizumab can better treat non-small cell lung cancer NSCLC with the KRAS G12C mutation. The study compares this combination to pembrolizumab with chemotherapy to see if it helps patients live longer without their cancer growing or spreading. This is a phase 3 clinical trial assessing treatment effectiveness and safety in participants with advanced or metastatic nonsquamous NSCLC. Participants will be randomly assigned to one of two groups. One group receives pembrolizumab plus berahyaluronidase alfa as a subcutaneous injection every 6 weeks for up to 18 cycles about 2 years, along with calderasib tablets until treatment discontinuation. The other group receives pembrolizumab plus berahyaluronidase alfa with chemotherapy drugs pemetrexed and either carboplatin or cisplatin given intravenously on specified days in the first cycles, also until discontinuation criteria are met. During the study, participants will have regular assessments including tumor scans and health questionnaires to monitor progression free survival, overall survival, response rates, and quality of life. Adverse events and treatment tolerability will also be tracked up to approximately 81 months. The study aims to provide detailed information on the impact of these treatments on cancer progression and patient well-being over time.
Actively Recruiting
Researchers are evaluating new treatments for people with locally advanced or metastatic urothelial cancer UC that has worsened after previous therapies. This phase 3 trial aims to find out if sacituzumab tirumotecan sac-TMT, an investigational drug given by intravenous infusion, can help patients live longer compared to standard non-platinum chemotherapy options. The study is sponsored by Merck Sharp & Dohme LLC. Participants are randomly assigned to receive either sacituzumab tirumotecan at 4 mgkg every two weeks via IV infusion or one of three chemotherapy drugspaclitaxel, docetaxel, or vinfluninegiven every three weeks by IV infusion. Treatment continues until the disease progresses or side effects become unacceptable. Rescue medications may be given as needed according to approved guidelines during treatment. During the trial, participants will have regular assessments including imaging to measure disease status and evaluations of side effects and quality of life. The main outcome measured is overall survival up to about 40 months, along with secondary outcomes like progression-free survival, response rates, duration of response, and changes in quality of life scores. Safety and adverse events will be monitored throughout, with the study lasting until April 2030.
Actively Recruiting
Researchers are comparing two treatment combinations for adults with advanced nonsquamous non-small cell lung cancer NSCLC that is stage IV or advanced stage IIIBC, specifically with a KRAS p.G12C mutation and no PD-L1 expression. The study evaluates progression-free survival and overall survival between participants receiving sotorasib with chemotherapy and those receiving pembrolizumab with chemotherapy. This is a phase 3, randomized, open-label study aiming to find which frontline therapy might better manage this type of lung cancer. Participants are randomly assigned to one of two groups one group receives sotorasib orally combined with carboplatin and pemetrexed chemotherapy, and the other group receives pembrolizumab given intravenously combined with the same chemotherapy agents. Treatments are given as front-line therapy for their cancer. The study measures the effects of these combinations over time, including tumor response and quality of life changes. During the study, participants will be closely monitored for progression-free survival, overall survival, and other outcomes related to tumor response and quality of life through questionnaires. Researchers will track treatment-emergent adverse events, vital signs, and lab tests to evaluate safety. The study includes follow-up assessments for up to approximately 5.5 years, allowing comprehensive evaluation of long-term outcomes and side effects. Participant involvement includes regular visits for treatment administration and assessments throughout the study period.
Actively Recruiting
Researchers are evaluating the clinical and endoscopic effects of guselkumab in children aged 2 to 17 with moderately to severely active Crohns Disease who responded to the treatment by Week 12. The study aims to assess the benefits of guselkumab after one year of maintenance therapy. This is a Phase 3 trial sponsored by Janssen Research & Development, LLC. Participants initially receive guselkumab either intravenously or subcutaneously according to their body weight during a 12-week open-label induction phase. Those who respond by Week 12 are then randomly assigned to one of two guselkumab subcutaneous dosing regimens for a double-blind maintenance phase lasting up to Week 48. Participants who do not respond by Week 12 enter an open-label maintenance phase receiving guselkumab subcutaneously up to Week 48. Throughout the study, participants undergo clinical evaluations, endoscopic assessments, and measurement of guselkumab levels at regular intervals up to Week 52. Researchers monitor changes in clinical remission, endoscopic response, growth parameters such as height and weight, and record any adverse events up to Week 64. The total participation duration extends to approximately one year, with ongoing safety and efficacy assessments.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of JNJ-78934804 compared to guselkumab in adults with moderately to severely active Crohns disease, a long-term and progressive intestinal condition. This Phase 3 study aims to assess how well these treatments work by measuring clinical and endoscopic remission at Week 48. The study is sponsored by Janssen Research & Development, LLC. Participants are randomly assigned to receive either JNJ-78934804 or guselkumab, both given as subcutaneous injections. Treatment starts with induction doses at Weeks 0, 4, and 8, followed by maintenance doses every 4 weeks from Week 12 onward. Those meeting rescue criteria during the study may receive additional induction doses of JNJ-78934804 at Weeks 16, 20, and 24, then continue maintenance dosing from Week 28. After completing the double-blind phase at Week 48, participants who may benefit can join a long-term extension phase. During the study, participants will undergo assessments to measure clinical remission, endoscopic remission, and other outcomes like deep remission and corticosteroid-free remission at various time points. Researchers will monitor patient-reported outcomes, adverse events, and serious adverse events for up to approximately three years. The study involves regular evaluations of disease activity and safety to understand treatment effects and participant well-being over time.
Actively Recruiting
Researchers are evaluating the use of mirikizumab in children and adolescents aged 2 to 17 years with moderately to severely active Crohns disease. The study aims to assess the drugs effectiveness, safety, tolerability, and how well it is absorbed in the body. This phase 3 clinical trial involves participants with confirmed Crohns disease or fistulizing Crohns disease who have shown an inadequate response or intolerance to at least one prior medication. Participants will receive mirikizumab intravenously or subcutaneously, with dosing based on their weight category. The study includes a 12-week induction period, followed by a maintenance phase lasting from week 12 to week 52. After the treatment periods, there is a safety follow-up period lasting up to 16 weeks. Overall, the study will last approximately 74 weeks and may involve up to 19 visits. Throughout the study, participants will undergo various assessments including clinical response evaluations using the Pediatric Crohns Disease Activity Index PCDAI and endoscopic scoring. Researchers will monitor changes in inflammatory markers such as C-reactive protein and fecal calprotectin, as well as pharmacokinetic measures of mirikizumab. Safety and tolerability will be tracked during the follow-up period, with all evaluations scheduled at multiple timepoints throughout the study.
Actively Recruiting
Researchers are evaluating the safety and effects of a new medicine called vepugratinib in adults with advanced or metastatic urothelial carcinoma, a type of bladder cancer with a specific FGFR3 genetic alteration. This phase 3 trial compares vepugratinib with a placebo when both are given alongside enfortumab vedotin and pembrolizumab. The study aims to understand if adding vepugratinib improves treatment outcomes and monitors adverse events over an extended period. Participants will receive oral vepugratinib or a matching placebo combined with intravenous enfortumab vedotin and pembrolizumab. The treatments are given in parallel groups, with some participants receiving the experimental drug and others the placebo, all alongside the standard IV therapies. The trial includes a safety lead-in phase and an extended treatment period, with study participation lasting up to approximately six years. During the trial, participants will undergo regular assessments including monitoring of treatment-related side effects, imaging to evaluate tumor response, blood tests to measure drug levels, and quality of life questionnaires. Researchers will track progression-free survival, overall survival, and response rates throughout the study and follow participants closely for safety and health status until study completion.
Actively Recruiting
Researchers are evaluating how well vortioxetine, given at doses of 10 mg or 20 mg daily, works compared to a placebo for treating depression symptoms in Japanese teenagers aged 12 to 17 years diagnosed with Major Depressive Disorder MDD. The study aims to assess both the effectiveness and side effects of the medication in this population. Participants will take either vortioxetine or a placebo orally once a day for 14 weeks. The treatment starts at 10 mg per day and may be increased to 20 mg per day. After the treatment period, there is a 4-week phase to monitor for any side effects. The study includes a total of 13 clinic visits during the participation period. Throughout the study, participants will be regularly assessed using various tools including the Children Depression Rating Scale Revised version CDRS-R, Patient Health Questionnaire-9 for Adolescents PHQ-A, Digit Symbol Substitution Test DSST, and Clinical Global Impression scales. Blood samples will be taken to measure plasma levels of vortioxetine. The entire participation lasts about 20 weeks, including up to 2 weeks for screening, 14 weeks of treatment, and 4 weeks of post-treatment follow-up to check safety.
Actively Recruiting
Non-small cell lung cancer NSCLC is a disease where cancer cells grow uncontrollably in lung tissues. This trial evaluates whether the investigational drug telisotuzumab vedotin works better than docetaxel and assesses its safety in adults with previously treated NSCLC that overexpresses c-Met. The study is a Phase 3 randomized trial involving about 768 participants worldwide to compare disease activity and side effects of these treatments. Participants will be randomly assigned to receive either telisotuzumab vedotin every two weeks or docetaxel every three weeks, both given as intravenous infusions. Treatment continues until specific discontinuation criteria are met. Those who benefit may have the option to continue treatment through an extension or rollover study. The study aims to compare how these two treatments affect disease progression and survival. During the study, participants will have regular hospital or clinic visits for medical assessments, blood tests, side effect monitoring, and questionnaires. Researchers will measure progression-free survival and overall survival up to about 39 months, along with response rates and quality of life indicators. The study includes detailed safety monitoring and may involve a higher treatment burden than standard care.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and changes in disease activity of an investigational drug called ABBV-706 compared to standard treatments for relapsed or refractory small cell lung cancer SCLC, a fast-growing cancer that often spreads early to other parts of the body. This Phase 3 trial involves about 531 adult participants worldwide and aims to assess how ABBV-706 works against current standard care options including topotecan, lurbinectedin, or amrubicin. Participants with SCLC will be randomly assigned to receive either ABBV-706 or one of the standard care treatments. ABBV-706 and the comparator drugs are given through intravenous infusion, with topotecan also available orally. The entire study is expected to last approximately 53 months, during which participants will receive their assigned treatment as part of this extended timeframe. During the study, participants will attend regular visits at a hospital or clinic for medical assessments, which include blood tests, scans, and questionnaires to monitor disease progression and treatment effects. Researchers will measure outcomes such as overall response rate, overall survival, progression-free survival, and quality of life changes. Safety and adverse events will be tracked throughout the study duration of up to 53 months.
1-10 of 31
1